tiprankstipranks
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H (HK:0874)
HKEX:0874
Holding HK:0874?
Track your performance easily

Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) Stock Price & Analysis

0 Followers

0874 Stock Chart & Stats


Options Prices

Currently, No data available
---

Ownership Overview

4.10%93.12%
Insiders
― Other Institutional Investors
93.12% Public Companies and
Individual Investors

0874 FAQ

What was Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price range in the past 12 months?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H lowest stock price was HK$16.62 and its highest was HK$24.20 in the past 12 months.
    What is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s market cap?
    Currently, no data Available
    When is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s upcoming earnings report date?
    Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s upcoming earnings report date is Mar 17, 2025 which is in 111 days.
      How were Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s earnings last quarter?
      Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H released its earnings results on Oct 25, 2024. The company reported HK$0.484 earnings per share for the quarter, the consensus estimate of HK$0.484 by HK$0.
        Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H overvalued?
        According to Wall Street analysts Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H pay dividends?
          Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H pays a Annually dividend of HK$0.44 which represents an annual dividend yield of 7.13%. See more information on Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H dividends here
            What is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s EPS estimate?
            Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s EPS estimate is HK$0.31.
              How many shares outstanding does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H have?
              Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H has 219,900,000 shares outstanding.
                What happened to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H’s price movement after its last earnings report?
                Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H reported an EPS of HK$0.484 in its last earnings report, expectations of HK$0.484. Following the earnings report the stock price went up 0.21%.
                  Which hedge fund is a major shareholder of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H?
                  Currently, no hedge funds are holding shares in HK:0874
                  ---

                  Guangzhou Baiyunshan Pharmaceutical Holdings Company Stock Smart Score

                  10
                  Unlock Smart Score
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Company Description

                  Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Class H

                  Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is active in the Chinese healthcare sector. The company manufactures pharmaceutical products including antibiotics, vasodilators, and traditional Chinese medical therapies in preparations such as injection, tablet, capsule, powder, cream, and oral liquid. Its operations are divided into three main segments: pharmaceutical manufacturing, pharmaceutical distribution & retail, and health products. The greater portion of its revenue comes from its pharmaceutical activities in patent medicine, raw materials, distribution, and retail. The rest of its revenues come from its beverage, food, cosmetics, and health products. The company's primary market is China.
                  ---

                  0874 Stock 12 Month Forecast

                  Average Price Target

                  HK$21.71
                  ▲(22.68% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"HK$15","22":"HK$22","16.75":"HK$16.75","18.5":"HK$18.5","20.25":"HK$20.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21.70000027429017,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$21.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.7135377,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$21.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.70000027429017,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$21.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,16.75,18.5,20.25,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2023","6":"Mar<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.34,18.598461559560782,18.856923119121564,19.115384678682346,19.37384623824313,19.63230779780391,19.890769357364693,20.149230916925475,20.407692476486258,20.66615403604704,20.924615595607822,21.183077155168604,21.441538714729386,{"y":21.70000027429017,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.34,18.5995029,18.8590058,19.1185087,19.3780116,19.637514499999998,19.8970174,20.1565203,20.416023199999998,20.6755261,20.935029,21.1945319,21.4540348,{"y":21.7135377,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.34,18.598461559560782,18.856923119121564,19.115384678682346,19.37384623824313,19.63230779780391,19.890769357364693,20.149230916925475,20.407692476486258,20.66615403604704,20.924615595607822,21.183077155168604,21.441538714729386,{"y":21.70000027429017,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.211,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.8,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.365,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.459,"date":1703808000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.318,"date":1704412800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.173,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19.941,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.776,"date":1717718400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.38,"date":1720137600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19.236,"date":1722556800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.949,"date":1726790400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.966,"date":1728000000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.34,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Guangzhou Baiyunshan Pharmaceutical Holdings Company
                  Shanghai Pharmaceuticals Holding Co
                  Sanofi
                  Zoetis
                  Pfizer
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis